We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

DOV:NYSEDover Corporation Analysis

Data as of 2026-08-22 - not real-time

$201.92

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Dover Corporation is priced at $201.92, and its moving averages give no clean directional read — the structure is neutral. Across the trailing 30 sessions it lost 6.2%. Momentum indicators put RSI at 40.5 (neutral) with MACD reading bearish. The recent range runs from support at $197.21 up to resistance at $214.57.
Valuation screens as undervalued: a P/E of 24.4 sits below the sector average of 29.9. The average analyst target implies 22.3% above today's level. Revenue is growing at 6.9% on a 13.5% profit margin. The 1.04% dividend yield looks covered by current payout levels.
Risk comes out at 5 of a possible 10, a moderate reading. With 30-day volatility of 32.1%, a beta of 0.94 and a maximum drawdown of 15.2%, position sizing matters here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Timeframes disagree: the short-term read is hold while the long-term read is buy, conviction 4 out of 10.

Top Market Events

Dover extended its five-quarter earnings beat streak with a $2.The Board of Directors of Dover Corporation NYSE: DOV today increased its quarterly cash dividend to $0.Dover Corporation NYSE: DOV today announced that it has signed a definitive agreement to acquire Leistung Engineering...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 1/10

Key Factors

  • Trading below the 200-day average of 209.22
  • MACD momentum is negative
  • 30-day price change of -6.2%

Medium Term

1–3 years
Neutral
Model confidence: 2/10

Key Factors

  • P/E of 24.4 versus sector average of 29.9
  • Trading below the 200-day average of 209.22
  • Analyst targets imply +22.3% versus the current price

Long Term

> 3 years
Positive
Model confidence: 4/10

Key Factors

  • P/E of 24.4 versus sector average of 29.9
  • Analyst targets imply +22.3% versus the current price
  • Dividend yield of 1.04%

Key Metrics & Analysis

Financial Health

Revenue Growth6.90%
Profit Margin13.48%
P/E Ratio24.4
ROE14.91%
ROA7.06%
Debt/Equity42.32
P/B Ratio3.5
Op. Cash Flow$1.4B
Free Cash Flow$906.5M
Industry P/E29.9

Technical Analysis

TrendNeutral
RSI40.5
Support$197.21
Resistance$214.57
MA 20$205.88
MA 50$212.59
MA 200$209.22
MACDBearish
VolumeDecreasing
Fear & Greed Index94.41

Valuation

Fair Value$104.36
Target Price$246.89
Upside/Downside22.27%
GradeUndervalued
TypeBlend
Dividend Yield1.04%

Risk Assessment

Beta0.94
Volatility32.07%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.